FDA’s Accelerated Approval Program creates an opportunity to bring promising treatments for serious conditions to patients sooner. Yet the pathway introduces a consequential planning challenge: the evidence that supports initial approval and the evidence required to verify clinical benefit must...
Expertise: Rare Disease 82 results
Rare Disease
Rare Trials Summit 2026
Expert speakers discuss operational, ethical, and regulatory factors that shape effective data-return strategies.
Rare Disease
Returning Patient Data in Rare Disease Studies
Returning individual results to participants is gaining momentum as a core expression of patient-centered research. In rare disease development, where participants often contribute significant time, personal risk, and emotional investment, access to personal study data is increasingly seen as part...
Learn how evolving FDA programs, modern trial designs, and patient-centered practices are reshaping rare disease development.
Navigating rare disease drug development requires coordinated, adaptive strategies as science and regulation evolve in parallel. Small, geographically dispersed patient populations, limited natural history data, and heterogeneous disease progression make trial design and execution unusually complex. At the same time,...